MedTrace Logo

Epcoritamab and Rituximab for First-line Follicular Lymphoma

NCT05783609 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-22

No results posted yet for this study

Summary

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma.

The names of the study drugs involved in this study are:

* Rituximab (a type of monoclonal antibody therapy)
* Epcoritamab (a T-cell bispecific antibody)

Conditions

Interventions

DRUG

Epcoritamab

T-cell bispecific antibody, via subcutaneous injection

DRUG

Rituximab

Chimeric anti-CD20 monoclonal antibody, via IV infusion

Sponsors & Collaborators

  • Genmab

    collaborator INDUSTRY

  • AbbVie

    collaborator INDUSTRY

  • Reid Merryman, MD

    lead OTHER

Principal Investigators

  • Reid Merryman, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-21
Primary Completion
2028-02-29
Completion
2030-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05783609 on ClinicalTrials.gov